Grant

ATB: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients

Sponsored by Atox Bio Ltd. (Israel)

$163.3K Funding

1 People

External

Related Topics

clinical trials, immunotherapy, patient safety, medical treatment, infection control

People

Lynn Gries
Principal Investigator (PI)
Surgery﹒Associate Professor